Keeping Risk in Context While Rethinking the Setting of Asthma Biologics in Patient-centered Care
Overview
Overview
Journal
Ann Allergy Asthma Immunol
Specialties
Allergy & Immunology
Pulmonary Medicine
Pulmonary Medicine
Date
2020 Jun 5
PMID
32497713
Citations
2
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Anaphylaxis knowledge gaps and future research priorities: A consensus report.
Dribin T, Schnadower D, Wang J, Camargo Jr C, Michelson K, Shaker M J Allergy Clin Immunol. 2021; 149(3):999-1009.
PMID: 34390722 PMC: 8837706. DOI: 10.1016/j.jaci.2021.07.035.
What the COVID-19 Pandemic Can Teach Us About Resource Stewardship and Quality in Health Care.
Abrams E, Singer A, Shaker M, Greenhawt M J Allergy Clin Immunol Pract. 2020; 9(2):608-612.
PMID: 33253924 PMC: 7691847. DOI: 10.1016/j.jaip.2020.11.033.
References
1.
Manka L, Wechsler M
. Selecting the right biologic for your patients with severe asthma. Ann Allergy Asthma Immunol. 2018; 121(4):406-413.
DOI: 10.1016/j.anai.2018.07.033.
View
2.
Li P, Kavati A, Puckett J, Jahnke J, Busse P, Hanania N
. Omalizumab Treatment Patterns Among Patients with Asthma in the US Medicare Population. J Allergy Clin Immunol Pract. 2019; 8(2):507-515.e10.
DOI: 10.1016/j.jaip.2019.07.011.
View
3.
Shaker M, Briggs A, Dbouk A, Dutille E, Oppenheimer J, Greenhawt M
. Estimation of Health and Economic Benefits of Clinic Versus Home Administration of Omalizumab and Mepolizumab. J Allergy Clin Immunol Pract. 2019; 8(2):565-572.
DOI: 10.1016/j.jaip.2019.09.037.
View
4.
Shaker M, Blatman K, Abrams E
. Engaging patient partners in state-of-the-art allergy care: Finding balance when discussing risk. Ann Allergy Asthma Immunol. 2020; 125(3):252-261.
DOI: 10.1016/j.anai.2020.01.029.
View
5.
Inselman J, Jeffery M, Maddux J, Shah N, Rank M
. Trends and Disparities in Asthma Biologic Use in the United States. J Allergy Clin Immunol Pract. 2019; 8(2):549-554.e1.
PMC: 7012665.
DOI: 10.1016/j.jaip.2019.08.024.
View